Corporate ActionJul 17, 2026, 04:11 PM
Transcode Therapeutics Increases Series C Preferred Stock Ownership Limit
AI Summary
Transcode Therapeutics, Inc. filed an Amended and Restated Certificate of Designation for its Series C Non-Voting Convertible Preferred Stock on July 16, 2026. This amendment increased the beneficial ownership limitation for holders of Series C Preferred Stock from 4.99% to 9.99%. The change was approved by the company's Board of Directors and a majority of the Series C Preferred Stock holders, with no new securities being issued or sold.
Key Highlights
- Transcode Therapeutics amended its Series C Preferred Stock Certificate of Designation.
- Beneficial ownership limit for Series C Preferred Stock increased from 4.99% to 9.99%.
- Amendment filed on July 16, 2026, with the Delaware Secretary of State.
- Approved by the Board of Directors and a majority of Series C Preferred Stock holders.
- No new securities were issued or sold in connection with this amendment.
- Original certificate filed March 2, 2026, related to Unleash Immuno Oncolytics agreements.
Price Impact
More from RNAZ